| ［1］ |
Zhang XJ, Chen JJ, Liu JB. The genetic concept of vitiligo［J］. J Dermatol Sci, 2005, 39（3）: 137⁃146. DOI: 10.1016/j.jdermsci.2005.06.004.
|
| ［2］ |
Kemp EH, Waterman EA, Weetman AP. Autoimmune aspects of vitiligo［J］. Autoimmunity, 2001, 34（1）: 65⁃77.
|
| ［3］ |
Hegedus L, Heildenheim M, Gervil M, et al. High frequency of thyroid dysfunction in patients with vitiligo［J］. Acta Derm Venereol, 1994, 74（2）: 120⁃123.
|
| ［4］ |
van den Boorn JG, Konijnenberg D, Dellemijn TA, et al. Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients［J］. J Invest Dermatol, 2009, 129（9）: 2220⁃2232. DOI: 10.1038/jid.2009.32.
|
| ［5］ |
Dwivedi M, Laddha NC, Arora P, et al. Decreased regulatory T⁃cells and CD4+/CD8+ ratio correlate with disease onset and progression in patients with generalized vitiligo［J］. Pigment Cell Melanoma Res, 2013, 26（4）: 586⁃591. DOI: 10.1111/pcmr.12105.
|
| ［6］ |
Lin M, Zhang BX, Shen N, et al. Regulatory T cells from active non⁃segmental vitiligo exhibit lower suppressive ability on CD8+CLA+ T cells［J］. Eur J Dermatol, 2014, 24（6）: 676⁃682. DOI: 10.1684/ejd.2014.2436.
|
| ［7］ |
Kotobuki Y, Tanemura A, Yang L, et al. Dysregulation of melanocyte function by Th17⁃related cytokines: significance of Th17 cell infiltration in autoimmune vitiligo vulgaris［J］. Pigment Cell Melanoma Res, 2012, 25（2）: 219⁃230. DOI: 10.1111/j.1755⁃148X.2011.00945.x.
|
| ［8］ |
Zhou L, Shi YL, Li K, et al. Increased circulating Th17 cells and elevated serum levels of TGF⁃beta and IL⁃21 are correlated with human non⁃segmental vitiligo development［J］. Pigment Cell Melanoma Res, 2015, 28（3）: 324⁃329. DOI: 10.1111/pcmr.12355.
|
| ［9］ |
Chatterjee S, Eby JM, Al⁃Khami AA, et al. A quantitative increase in regulatory T cells controls development of vitiligo［J］. J Invest Dermatol, 2014, 134（5）: 1285⁃1294. DOI: 10.1038/jid.2013.540.
|
| ［10］ |
Rashighi M, Agarwal P, Richmond JM, et al. CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo［J］. Sci Transl Med, 2014, 6（223）: 223ra23. DOI: 10.1126/scitranslmed.3007811.
|
| ［11］ |
Mosenson JA, Flood K, Klarquist J, et al. Preferential secretion of inducible HSP70 by vitiligo melanocytes under stress［J］. Pigment Cell Melanoma Res, 2014, 27（2）: 209⁃220. DOI: 10.1111/pcmr.12208.
|
| ［12］ |
Mosenson JA, Zloza A, Nieland JD, et al. Mutant HSP70 reverses autoimmune depigmentation in vitiligo［J］. Sci Transl Med, 2013, 5（174）: 174ra28. DOI: 10.1126/scitranslmed.3005127.
|
| ［13］ |
Richmond JM, Frisoli ML, Harris JE. Innate immune mechanisms in vitiligo: danger from within［J］. Curr Opin Immunol, 2013, 25（6）: 676⁃682. DOI: 10.1016/j.coi.2013.10.010.
|
| ［14］ |
Yu R, Broady R, Huang Y, et al. Transcriptome analysis reveals markers of aberrantly activated innate immunity in vitiligolesional and non⁃lesional skin［J］. PLoS One, 2012, 7（12）: e51040. DOI: 10.1371/journal.pone.0051040.
|
| ［15］ |
Marie J, Kovacs D, Pain C, et al. Inflammasome activation and vitiligo/nonsegmental vitiligo progression［J］. Br J Dermatol, 2014, 170（4）: 816⁃823. DOI: 10.1111/bjd.12691.
|
| ［16］ |
Bertolotti A, Boniface K, Vergier B, et al. Type I interferon signature in the initiation of the immune response in vitiligo［J］. Pigment Cell Melanoma Res, 2014, 27（3）: 398⁃407. DOI: 10.1111/pcmr.12219.
|
| ［17］ |
Shi Q, Zhang W, Guo S, et al. Oxidative stress⁃induced overex⁃pression of miR⁃25: the mechanism underlying the degeneration of melanocytes in vitiligo［J］. Cell Death Differ, 2016, 23（3）: 496⁃508. DOI: 10.1038/cdd.2015.117.
|
| ［18］ |
Al⁃Shobaili HA, Rasheed Z. Oxidized tyrosinase: a possible antigenic stimulus for non⁃segmental vitiligo autoantibodies［J］. J DermatolSci, 2015, 79（3）: 203⁃213. DOI: 10.1016/j.jdermsci.2015.06.009.
|
| ［19］ |
Laddha NC, Dwivedi M, Mansuri MS, et al. Role of oxidative stress and autoimmunity in onset and progression of vitiligo［J］. Exp Dermatol, 2014, 23（5）: 352⁃353. DOI: 10.1111/exd.12372.
|
| ［20］ |
Wang X, Du J, Wang T, et al. Prevalence and clinical profile of vitiligo in China: a community⁃based study in six cities［J］. ActaDermVenereol, 2013, 93（1）: 62⁃65. DOI: 10.2340/00015555⁃1397.
|
| ［21］ |
Spritz RA. Modern vitiligo genetics sheds new light on an ancient disease［J］. J Dermatol, 2013, 40（5）: 310⁃318. DOI: 10.1111/1346⁃8138.12147.
|
| ［22］ |
Quan C, Ren YQ, Xiang LH, et al. Genome⁃wide association study for vitiligo identifies susceptibility loci at 6q27 and the MHC［J］. Nat Genet, 2010, 42（7）: 614⁃618. DOI: 10.1038/ng.603.
|
| ［23］ |
Tang XF, Zhang Z, Hu DY, et al. Association analyses identify three susceptibility Loci for vitiligo in the Chinese hanpopulation［J］. J Invest Dermatol, 2013, 133（2）: 403⁃410. DOI: 10.1038/jid.2012.320.
|
| ［24］ |
Huang Y, Yi X, Jian Z, et al. A single⁃nucleotide polymorphism of miR⁃196a⁃2 and vitiligo: an association study and functional analysis in a Han Chinese population［J］. Pigment Cell Melanoma Res, 2013, 26（3）: 338⁃347. DOI: 10.1111/pcmr.12081.
|
| ［25］ |
Webb KC, Tung R, Winterfield LS, et al. Tumour necrosis factor⁃α inhibition can stabilize disease in progressive vitiligo［J］. Br J Dermatol, 2015, 173（3）: 641⁃650. DOI: 10.1111/bjd.14016.
|
| ［26］ |
Camara⁃Lemarroy CR, Salas⁃Alanis JC. The role of tumor necrosis factor⁃α in the pathogenesis of vitiligo［J］. Am J ClinDermatol, 2013, 14（5）: 343⁃350. DOI: 10.1007/s40257⁃013⁃0039⁃3.
|
| ［27］ |
Singh RK, Lee KM, Vujkovic⁃Cvijin I, et al. The role of IL⁃17 in vitiligo: a review［J］. Autoimmun Rev, 2016, 15（4）:397⁃404.
|
| ［28］ |
Wang S, Zhou M, Lin F, et al. Interferon⁃γ induces senescence in normal human melanocytes［J］. PLoS One, 2014, 9（3）: e93232. DOI: 10.1371/journal.pone.0093232.
|
| ［29］ |
Ning W, Wang S, Dong X, et al. Epigallocatechin⁃3⁃gallate （EGCG） suppresses the trafficking of lymphocytes to epidermal melanocytes via inhibition of JAK2: its implication for vitiligo treatment［J］. Biol Pharm Bull, 2015, 38（11）: 1700⁃1706. DOI: 10.1248/bpb.b15⁃00331.
|
| ［30］ |
Craiglow BG, King BA. Tofacitinib citrate for the treatment of vitiligo: a pathogenesis⁃directed therapy［J］. JAMA Dermatol, 2015, 151（10）: 1110⁃1112. DOI: 10.1001/jamadermatol.2015.1520.
|
| ［31］ |
Harris JE, Rashighi M, Nguyen NR et al. Rapid skin repig⁃mentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata （AA）［J］. J Am Acad Dermatol, 2016, 74（2）: 370⁃371.
|
